Moderate

Chronic hyperkalaemia — outpatient management

chronic hyperK · Renal / Electrolyte
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

Persistent mild-to-moderate hyperkalaemia in CKD, diabetes or on RAAS/MRA therapy, managed to allow continuation of prognostically important drugs while avoiding dangerous peaks. Dietary measures, drug review and potassium binders are the mainstays.

Figures & algorithms

ECG changes
ECG changes

Red flags

  • Potassium >=6.5 mmol/L or ECG changes (peaked T waves, widened QRS)
  • Muscle weakness or paralysis
  • Rapidly rising potassium
  • New bradyarrhythmia
  • Oliguria/AKI superimposed on CKD

Assessment

Differential diagnosis

  • CKD with reduced potassium excretion
  • RAAS inhibitor / MRA / potassium-sparing diuretic effect
  • Type 4 RTA (hyporeninaemic hypoaldosteronism, diabetes)
  • Metabolic acidosis shifting potassium out
  • Dietary potassium excess / supplements
  • Pseudohyperkalaemia (haemolysed sample, thrombocytosis)

Investigations

  • Repeat serum potassium on a non-haemolysed sample (exclude pseudohyperkalaemia)
  • U&E, eGFR and bicarbonate
  • ECG if potassium >=6.0 or symptomatic
  • Medication and diet review
  • Glucose/HbA1c (consider type 4 RTA in diabetes)
  • Urinary potassium / aldosterone if cause unclear

Management

  • Confirm true hyperkalaemia and exclude pseudohyperkalaemia (haemolysis, fist-clenching, delayed processing)
  • Assess acuity: obtain an ECG and treat as an emergency if potassium >=6.5 or ECG changes
  • Review medications: potassium supplements, NSAIDs, trimethoprim, and the balance of RAAS/MRA benefit vs risk
  • Provide dietary potassium education (limit high-potassium foods, cooking methods) via a dietitian
  • Correct metabolic acidosis with oral sodium bicarbonate to shift potassium and aid excretion
  • Optimise volume/use of a loop or thiazide diuretic to enhance kaliuresis where appropriate
  • Add a potassium binder (patiromer or sodium zirconium cyclosilicate) to enable continuation of RAAS/MRA therapy
  • Avoid routinely stopping prognostically important RAAS/MRA drugs — down-titrate and bind potassium instead where feasible
  • Treat underlying type 4 RTA (fludrocortisone in selected cases) if present
  • Monitor potassium after each change and periodically thereafter
  • Give sick-day advice to hold RAAS blockade during dehydrating illnesses
  • Escalate to nephrology for refractory or severe hyperkalaemia

Drugs & doses

Patiromer 8.4 g PO once daily, titrated (chronic potassium binder)
Sodium zirconium cyclosilicate 5-10 g PO once daily maintenance
Sodium bicarbonate 500-1000 mg PO two to three times daily (acidosis)
Furosemide 20-80 mg PO daily (enhance kaliuresis if volume permits)
Fludrocortisone 50-100 micrograms PO daily (selected type 4 RTA)

Disposition

Primary care/CKD clinic with dietitian input. Emergency treatment for potassium >=6.5 or ECG changes. Nephrology referral for refractory hyperkalaemia.

Complications & pitfalls

  • Life-threatening arrhythmia
  • Forced discontinuation of beneficial RAAS/MRA therapy
  • GI side effects of binders
  • Sodium/volume load from binders in heart failure
  • Recurrent acute hyperkalaemia episodes

Exam pearls

  • Exclude pseudohyperkalaemia before acting on a surprising result
  • Potassium binders let patients stay on prognostically important RAAS/MRA therapy
  • Correcting acidosis improves potassium handling
  • Trimethoprim and NSAIDs are common hidden culprits
  • Give explicit sick-day rules to pause RAAS blockade during acute illness

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.